Suppression of Rev3, the catalytic subunit of Pol?, sensitizes drug-resistant lung tumors to chemotherapy

Jason Doles, Trudy G. Oliver, Eleanor R. Cameron, Gerald Hsu, Tyler Jacks, Graham C. Walker, Michael T. Hemann

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Pol?, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Pol?, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.

Original languageEnglish (US)
Pages (from-to)20786-20791
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume107
Issue number48
DOIs
StatePublished - Nov 30 2010
Externally publishedYes

Fingerprint

Catalytic Domain
Cisplatin
Drug Therapy
Lung
Pharmaceutical Preparations
Neoplasms
Transplantation
Therapeutics
Platinum
Tumor Cell Line
Drug Resistance
Non-Small Cell Lung Carcinoma
Lung Neoplasms
Mutation
DNA

Keywords

  • Error-prone synthesis
  • Mouse models
  • RNA interference

ASJC Scopus subject areas

  • General

Cite this

Suppression of Rev3, the catalytic subunit of Pol?, sensitizes drug-resistant lung tumors to chemotherapy. / Doles, Jason; Oliver, Trudy G.; Cameron, Eleanor R.; Hsu, Gerald; Jacks, Tyler; Walker, Graham C.; Hemann, Michael T.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, No. 48, 30.11.2010, p. 20786-20791.

Research output: Contribution to journalArticle

Doles, Jason ; Oliver, Trudy G. ; Cameron, Eleanor R. ; Hsu, Gerald ; Jacks, Tyler ; Walker, Graham C. ; Hemann, Michael T. / Suppression of Rev3, the catalytic subunit of Pol?, sensitizes drug-resistant lung tumors to chemotherapy. In: Proceedings of the National Academy of Sciences of the United States of America. 2010 ; Vol. 107, No. 48. pp. 20786-20791.
@article{cf985630536b445bb7da586433036fbf,
title = "Suppression of Rev3, the catalytic subunit of Pol?, sensitizes drug-resistant lung tumors to chemotherapy",
abstract = "Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Pol?, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Pol?, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.",
keywords = "Error-prone synthesis, Mouse models, RNA interference",
author = "Jason Doles and Oliver, {Trudy G.} and Cameron, {Eleanor R.} and Gerald Hsu and Tyler Jacks and Walker, {Graham C.} and Hemann, {Michael T.}",
year = "2010",
month = "11",
day = "30",
doi = "10.1073/pnas.1011409107",
language = "English (US)",
volume = "107",
pages = "20786--20791",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "48",

}

TY - JOUR

T1 - Suppression of Rev3, the catalytic subunit of Pol?, sensitizes drug-resistant lung tumors to chemotherapy

AU - Doles, Jason

AU - Oliver, Trudy G.

AU - Cameron, Eleanor R.

AU - Hsu, Gerald

AU - Jacks, Tyler

AU - Walker, Graham C.

AU - Hemann, Michael T.

PY - 2010/11/30

Y1 - 2010/11/30

N2 - Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Pol?, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Pol?, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.

AB - Platinum-based chemotherapeutic drugs are front-line therapies for the treatment of non-small cell lung cancer. However, intrinsic drug resistance limits the clinical efficacy of these agents. Recent evidence suggests that loss of the translesion polymerase, Pol?, can sensitize tumor cell lines to cisplatin, although the relevance of these findings to the treatment of chemoresistant tumors in vivo has remained unclear. Here, we describe a tumor transplantation approach that enables the rapid introduction of defined genetic lesions into a preclinical model of lung adenocarcinoma. Using this approach, we examined the effect of impaired translesion DNA synthesis on cisplatin response in aggressive late-stage lung cancers. In the presence of reduced levels of Rev3, an essential component of Pol?, tumors exhibited pronounced sensitivity to cisplatin, leading to a significant extension in overall survival of treated recipient mice. Additionally, treated Rev3-deficient cells exhibited reduced cisplatin-induced mutation, a process that has been implicated in the induction of secondary malignancies following chemotherapy. Taken together, our data illustrate the potential of Rev3 inhibition as an adjuvant therapy for the treatment of chemoresistant malignancies, and highlight the utility of rapid transplantation methodologies for evaluating mechanisms of chemotherapeutic resistance in preclinical settings.

KW - Error-prone synthesis

KW - Mouse models

KW - RNA interference

UR - http://www.scopus.com/inward/record.url?scp=78650575542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650575542&partnerID=8YFLogxK

U2 - 10.1073/pnas.1011409107

DO - 10.1073/pnas.1011409107

M3 - Article

VL - 107

SP - 20786

EP - 20791

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 48

ER -